The US FDA has approved mitapivat, the first oral drug to target red blood cell energy metabolism for treating anemia in thalassaemia. This marks a potential shift from traditional blood transfusions and iron chelation, offering cautious optimism for adult patients. While promising, questions about its effectiveness, safety, affordability, and accessibility, particularly in high-burden countries like India, are being raised as newer therapies emerge.